Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Dana-Farber Cancer Institute | OTHER |
| Brigham and Women's Hospital | OTHER |
| Beth Israel Deaconess Medical Center | OTHER |
| Metro West Medical Center |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this research study is to assess outcomes of treatment for early prostate cancer. Current treatments for early (non-metastatic) cancer may cause long-term impairments in the patients quality of life. In this study we will compare the outcomes of patients treated with two alternative brachytherapy (seed implants) techniques using a series of questionnaires.
Participants will be asked to complete a questionnaire about their health prior to treatment, at 1, 3 and 12 months after treatment and then once a year 4 more times.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| MRBT | MRI-assisted brachytherapy, the experimental arm |
| |
| USBT1 | Standard ultrasound-guided brachytherapy performed by group 1 (control arm 1) |
| |
| USBT2 | Standard ultrasound-guided brachytherapy performed by group 2 (control group 2) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| brachytherapy | Radiation | An experimental arm using MRI imaging and excluding the transition zone from the target volume |
|
| Measure | Description | Time Frame |
|---|---|---|
| To assess changes in generic and disease specific quality of life over time after treatment with brachytherapy for early prostate cancer | 10 years |
| Measure | Description | Time Frame |
|---|---|---|
| To compare these outcomes after two alternative brachytherapy techniques, standard ultrasound guided brachytherapy and MRI guided prostate brachytherapy (MRIGPB) | 10 years | |
| To identify factors associated with specific adverse outcomes. | 10 years |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients who have indicated their intention to receive brachytherapy at one of the four accrual sites.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| James Talcott, MD, SM | Contact | 617-724-5451 | jtalcott@partners.org | |
| Anita Rodrigues | Contact | aerodrigues@partners.org |
| Name | Affiliation | Role |
|---|---|---|
| James Talcott, MD, SM | Massachusetts General Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Massachusetts General Hospital | Recruiting | Boston | Massachusetts | 02114 | United States |
Not provided
| ID | Term |
|---|---|
| D011471 | Prostatic Neoplasms |
| ID | Term |
|---|---|
| D005834 | Genital Neoplasms, Male |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
| ID | Term |
|---|---|
| D001918 | Brachytherapy |
| ID | Term |
|---|---|
| D011878 | Radiotherapy |
| D013812 | Therapeutics |
Not provided
Not provided
| OTHER |
| United States Department of Defense | FED |
Not provided
Not provided
Not provided
| brachytherapy | Radiation | Standard ultrasound-guided brachytherapy with standard target volumes |
|
| brachytherapy | Radiation | Standard ultrasound-guided brachytherapy with standard target volumes |
|
| Dana-Farber Cancer Institute/Brigham and Women's Hospital | Recruiting | Boston | Massachusetts | 02115 | United States |
|
| Beth Israel Deaconess Medical Center | Recruiting | Boston | Massachusetts | 02215 | United States |
|
| D005832 |
| Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D011469 | Prostatic Diseases |
| D052801 | Male Urogenital Diseases |